Novartis will be closely watching today's expert panel session [1] at the FDA on Arcoxia, Merck's hoped-for successor to Vioxx. Their vote could have a big impact on Novartis' chances of successfully developing Prexige. Report [2]
Links:
[1] http://www.fiercebiotech.com/story/fda-panel-to-consider-case-for-arcoxia/2007-04-09
[2] http://investing.reuters.co.uk/news/articleinvesting.aspx?type=health&storyID=2007-04-11T170155Z_01_L11599312_RTRIDST_0_SP_PAGE_015-L11599312-OISHE.XML